Best treatment strategies in high-risk multiple myeloma: Navigating a gray area

Journal of Clinical Oncology

Volumn 32, Issue 20, 2014, Pages 2125-2132

  Bianchi, Giada ^a   Richardson, Paul G ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CONGO RED; DEXAMETHASONE; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE; PARAPROTEIN; PLASMA PROTEIN; ZOLEDRONIC ACID;

ADULT; ARTICLE; BACKACHE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CYTOGENETICS; ELECTROPHORESIS; FATIGUE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MALE; MEAN CORPUSCULAR VOLUME; META ANALYSIS (TOPIC); MIDDLE AGED; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; PALLOR; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERUM PROTEIN ELECTROPHORESIS; URINE PROTEIN ELECTROPHORESIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BACK PAIN; BIOPSY; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; BORONIC ACIDS; DEXAMETHASONE; DIPHOSPHONATES; FATIGUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LAMBDA-CHAINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PYRAZINES; REFERRAL AND CONSULTATION; THALIDOMIDE; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84905842882     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.7900     Document Type: Article

References (54)

1. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med 364:1046-1060, 2011
2. American Cancer Society: Multiple Myeloma Overview. American Cancer Society, 2012
3. Kyle RA, Rajkumar SV: Multiple myeloma. Blood 111:2962-2972, 2008
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008
5. Anderson KC: The 39th David A. Karnofsky Lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30:445-452, 2012
6. Stewart AK, Richardson PG, San-Miguel JF: How I treat multiple myeloma in younger patients. Blood 114:5436-5443, 2009
7. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Français du Myélome. N Engl J Med 335:91-97, 1996 (Pubitemid 26240110)
8. Child JA, Morgan GJ, Davies FE, et al: Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003 (Pubitemid 36532313)
9. Fermand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227-9233, 2005
10. Bladé J, Rosiñol L, Sureda A, et al: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Longterm results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755-3759, 2005 (Pubitemid 41739009)
11. Koreth J, Cutler CS, Djulbegovic B, et al: High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and metaanalysis of randomized controlled trials. Biol Blood Marrow Transplant 13:183-196, 2007 (Pubitemid 46112369)
12. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003 (Pubitemid 38010075)
13. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356:1110-1120, 2007 (Pubitemid 46425595)
14. Lokhorst H, Einsele H, Vesole D, et al: International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 28:4521-4530, 2010
15. Avet-Loiseau H: Ultra high-risk myeloma. Hematology Am Soc Hematol Educ Program 2010:489-493, 2010
16. Bergsagel PL, Mateos MV, Gutierrez NC, et al: Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 121:884-892, 2013
17. Cavo M, Terragna C, Renzulli M, et al: Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: Low complete remission rate and short duration of remission. J Clin Oncol 24:e4-e5, 2006
18. Gertz MA, Lacy MQ, Dispenzieri A, et al: Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 106:2837-2840, 2005 (Pubitemid 41510761)
19. Avet-Loiseau H, Leleu X, Roussel M, et al: Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630-4634, 2010
20. Neben K, Lokhorst HM, Jauch A, et al: Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119:940-948, 2012
21. Cavo M, Pantani L, Petrucci MT, et al: Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 120:9-19, 2012
22. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30:2946-2955, 2012
23. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782-1791, 2012
24. Cavo M, Tacchetti P, Patriarca F, et al: Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study. Lancet 376:2075-2085, 2010
25. Harousseau JL, Attal M, Avet-Loiseau H, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol 28:4621-4629, 2010
26. Rosiñol L, Oriol A, Teruel AI, et al: Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/ GEM study. Blood 120:1589-1596, 2012
27. Morgan GJ, Davies FE, Gregory WM, et al: Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 97:442-450, 2012
28. Morgan GJ, Davies FE, Gregory WM, et al: Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 19:6030-6038, 2013
29. Pineda-Roman M, Zangari M, Haessler J, et al: Sustained complete remissions in multiple myeloma linked to bortezomib in Total Therapy 3: Comparison with Total Therapy 2. Br J Haematol 140:625-634, 2008 (Pubitemid 351300910)
30. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
31. Morgan GJ, Gregory WM, Davies FE, et al: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7-15, 2012
32. Barlogie B, Pineda-Roman M, van Rhee F, et al: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115-3121, 2008
33. van de Velde HJ, Liu X, Chen G, et al: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92:1399-1406, 2007 (Pubitemid 350144158)
34. Martinez-Lopez J, Blade J, Mateos MV, et al: Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118:529-534, 2011
35. Hoering A, Crowley J, Shaughnessy JD Jr, et al: Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. Blood 114:1299-1305, 2009
36. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
37. Kapoor P, Kumar SK, Dispenzieri A, et al: Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol 31:4529-4535, 2013
38. Rawstron AC, Child JA, de Tute RM, et al: Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 31:2540-2547, 2013
39. Paiva B, Gutiérrez NC, Rosiñol L, et al: Highrisk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119:687-691, 2012
40. Dunavin NC, Wei L, Elder P, et al: Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma 54:1658-1664, 2013
41. Kumar SK, Lacy MQ, Dispenzieri A, et al: Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 118:1585-1592, 2012
42. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116:679-686, 2010
43. Inamoto Y, Kurahashi S, Imahashi N, et al: Combinations of cytogenetics and International Scoring System can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. Am J Hematol 84:283-286, 2009
44. Hari PN, Zhang MJ, Roy V, et al: Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 23:1528-1534, 2009
45. Maltezas D, Dimopoulos MA, Katodritou I, et al: Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematol Oncol 31:356-362, 2013
46. Moreau P, Cavo M, Sonneveld P, et al: Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma treated with front-line autologous stem-cell transplantation at high risk of early multiple myeloma progression-related death. J Clin Oncol 32:2173-2180, 2014
47. Facon T, Dimopoulos MA, Dispenzieri A, et al: Initial phase 3 results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma (NDMM) patients (Pts) ineligible for stem cell transplantation (SCT). Blood 122, 2013 (abstr 2)
48. Rajkumar SV, Jacobus S, Callander NS, et al: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 11:29-37, 2010
49. Rajkumar SV: Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 88:226-235, 2013
50. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759-1769, 2012
51. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770-1781, 2012
52. Nooka AK, Kaufman JL, Muppidi S, et al: Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28:690-693, 2014
53. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncol 12:431-440, 2011
54. Richardson PG, Laubach J, Mitsiades CS, et al: Managing multiple myeloma: The emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol 154:755-762, 2011